Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4779532 | 0.90 | KCNH2 (0.41) | KCNH2 | |
| SCHEMBL4775988 | 0.89 | KCNH2 (0.51) | KCNH2 | |
| SCHEMBL4296835 | 0.88 | KCNH2 (0.56) | KCNH2SLC2A1 | |
| SCHEMBL2798116 | 0.86 | KCNH2 (0.49) | KCNH2 | |
| SCHEMBL4775755 | 0.83 | KCNH2 (0.41) | KCNH2 | |
| SCHEMBL4778712 | 0.83 | KCNH2 (0.57) | KCNH2 | |
| SCHEMBL4778509 | 0.82 | KCNH2 (0.51) | KCNH2 | |
| SCHEMBL4297655 | 0.82 | KCNH2 (0.51) | KCNH2SLC2A1 | |
| SCHEMBL2798079 | 0.82 | SHH (0.36) | KCNH2 | |
| SCHEMBL4136611 | 0.81 | KCNH2 (0.54) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071592-B2 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | ETFA, NQO2, GNAQ | KCNH2 2142/4885SLC2A1 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.